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Open access unda b s t r a c t
Major Depressive Disorder (MDD) is a highly recurrent disease. Stress-responsive system dysfunction
seems to persist after remission. In patients with more chronic and recurrent depressive episodes, state
related HPA-axis dysregulation might be a risk factor for prospective recurrence. This study examines
the predictive effect of cortisol on consecutive episodes in remitted recurrently depressed patients.
Cortisol was assessed in saliva in remitted recurrently depressed patients (n¼55) that were
followed up prospectively for 5.5 years after remission. Recurrence was assessed using a well validated
structured interview.
Lower mean morning cortisol levels predicted earlier time to recurrence over 5.5 year after
correction for residual symptoms (p¼0.015). Residual symptoms and childhood trauma slightly con-
founded the association between cortisol and recurrence. Lower cortisol levels were associated with
having experienced traumatic childhood life events (42.3% in patients with lower cortisol versus 19.2%
in patients with higher cortisol).
Our study provides further support for the predictive role over 5.5 year of HPA axis dysregulation,
i.e. lower morning cortisol levels, of recurrence in recurrently depressed patients. Childhood trauma is
associated to having lower cortisol levels. It might have long term consequences for dealing with stress
and the HPA-axis.
& 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Major Depressive Disorder (MDD) is a highly recurrent disease.
In the absence of prophylactic treatment, the rate of recurrence rises
up to 80 percent (Frank et al.,1990). Therefore identifying predictors
of recurrence and examining pathogenic mechanism of recurrence
is essential. Stress has been considered as one of the cardinal
pathogenic factors involved in MDD and its recurrence: childhood
and recent life events, daily hassles, stress related to previous
episodes and aberrant coping, all pose increased risks for MDD
and its recurrences (Kessler, 1997; Kendler, Thornton, Gardner,
2001; Bockting et al., 2006a,b; Ten Doesschate et al. 2010; Nanni,
Uher and Danese, 2012). Furthermore, stress reducing cognitive
therapy (CT) has a beniﬁcial effect in preventing recurrence
(Bockting et al., 2005, 2009; Vittengl et al., 2007; Guidi et al., 2011).
The hypothalamic pituitary adrenal (HPA) axis is the major
neuroendocrine stress response system. Stress-responsive systemmain.asp?pid¼70.
: þ31 503637602.
ting).
er the Elsevier OA license.dysfunction seems to persist after remission of acute depression.
The dynamics associated with the course of the illness have not
been thoroughly studied yet. Persistent dysregulation of the HPA
axis after remission of depression may represent a trait-marker
for the risk of recurrent depressive episodes (Modell et al., 1998,
Goodyer et al., 2000; Zobel et al., 2001; Appelhof et al., 2006;
Mannie et al., 2007).
Mixed ﬁndings have been reported for the role of cortisol.
A previous ﬁnding of our group indicated that in remitted patients
with major depression, higher posttreatment maximal cortisol levels
on the DEX/CRH test were associated with relapse and with shorter
relapse-free survival in a mixed outpatient group with the ﬁrst
and recurrent episodes (Appelhof et al., 2006). In addition, the
proportion of remitted patients showing a persistent DST non-
suppression were suggested to be more vulnerable to early relapse
and recurrence, have poor outcome after discharge and suffer more
often from persistent depression (Ribeiro et al., 1993; O’Toole and
Johnson, 1997; Zobel et al., 1999). Hypercortisolism has also been
reported by Zobel et al. (2001) as a marker for vulnerability for
relapse and recurrence in previously depressed patients.
However, hypocortisolism has been reported as well; a phenom-
enon that is characterized by a hyporesponsiveness on different levels
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(2005) stated in their overview. It was ﬁrst reported in the eighties by
using single-dose metyrapone test in depressed patients (Fava et al.,
1984; Fava, 1994). Recently, Vreeburg (2010) studied in a longitudinal
study including 837 patients with depressive and/or anxiety
disorders, the association between salivary cortisol measures at
baseline and the course of psychopathology. The patients with a
lower cortisol awakening response were at a higher risk of
developing a chronic course, compared to persons experiencing
remission during the two-year follow up. Evening cortisol
and cortisol suppression after dexamethasone intake were not
associated with a chronic course. The association appeared to be
similar across disorders (anxiety disorder, depressive disorder
or co-morbid disorders). Another study found stable hyporeac-
tivity of the HPA over one year in depressed women on
job-stress-related long-term sick leave compared with controls
(Wahlberg et al., 2009). Moreover, Sondeijker et al. (2008)
reported over a study including young, not depressed adoles-
cents, that low morning cortisol levels predicted future
psychopathology.
In patients with more chronic or recurrent depressive episodes,
state related HPA-axis dysregulation might be reﬂected in a cortisol
hyposecretion when compared to non-depressed control-subjects
(Oldehinkel et al., 2001). In a remitted recurrently depressed cohort
of women, HPA system hypoactivity was found, both in the basal
state and in response to a psychosocial stressor when compared to
healthy subjects (Ahrens et al., 2008). In other disorders associated
with chronic stress, such as posttraumatic stress disorder, cortisol
hyposecretion has also been reported (Yehuda et al., 1990) and for a
meta-analysis see (Meewisse et al., 2007). The impact of chronic
stress in recurrent depression could explain why a low HPA-Axis
activity could be a risk factor for recurrence.
There have been at least 361 studies performed that compared
HPA axis function between depressed and non-depressed indivi-
duals, however few studies examined the predictive value of the
HPA activity on course in recurrent and chronic depression (for a
meta-analysis see Stetler and Miller, 2011). The current long-
itudinal study examined the role of the HPA axis on prospective
recurrence over 5.5 years in remitted patients with recurrent
depression (i.e. having at least 2 previous episodes). All patients
(N¼172) achieved a good remission state at entry of the study
(i.e. not meeting criteria of a depressive episode according to the
DSM-IV-TR criteria and a HRSD score less than 10), though
residual symptoms are common after remission in depression
(Beshai et al., 2011; Fava, 1999). Since cortisol levels are
considered as rather state dependent, controlling for residual
depressive symptoms in these remitted patients is necessary
(Ribeiro et al., 1993). We aimed to determine (I) whether HPA-
axis measures predict time to recurrence in remitted recurrently
depressed patients corrected for residual depressive symptoms.
In line with the previous studies on chronic recurrent depression
we expect that in this highly recurrent remitted MDD group lower
cortisol levels predict prospective recurrence over 5.5 year.
Stress and childhood trauma might affect the predictive value
of the HPA-axis on recurrence (Ormel et al., 2001; Carpenter
et al., 2009). Therefore, (II) we will examine the role of stress
(current daily hassles) and childhood trauma on the predictive
value of the HPA-axis on recurrence.2. Methods
2.1. Participants and procedure
For this study we included patients from a clinical trial in which the effect of
regular care (including no care at all) on recurrence was compared to regular care
with additional preventive cognitive therapy (Bockting et al., 2005). To be eligiblefor the trial, subjects had to meet the following criteria: (a) at least two Major
Depressive Episodes (MDEs) in the last ﬁve years, as deﬁned according to DSM-IV
(1994) and assessed by the Structured Clinical Interview for DSM-IV (SCID,
First et al., 1996) by trained evaluators; (b) current remission status according
to DSM-IV criteria, for longer than 10 weeks and no longer than two years ago;
(c) Hamilton Rating Scale for Depression (Hamilton, 1960) of o10 (as is common
in relapse/recurrence prevention studies). Exclusion criteria were current mania
or hypomania or a history of bipolar illness, any psychotic disorder (current and
previous), organic brain damage, alcohol or drug misuse, predominant anxiety
disorder, recent ECT, recent Cognitive Therapy (CT) or receiving CT at the start of
the study, or current psychotherapy with a frequency of more than two times a
month. Co-morbidity on axis I was assessed using the SCID (First et al., 1996).
There was no restriction in using pharmacotherapy (the effect of use will
be examined). Participants were recruited at psychiatric centers and through
media announcement. They provided informed consent to enter the protocol.
The protocol was approved by the institutional ethics review committees. We
were able to collect HPA-axis baseline data from 55 patients in the control group
(N¼84; regular care only). More detail about participants, recruitment, inclusion
and exclusion criteria are available in Bockting et al. (2005).2.2. Study measures
2.2.1. Inclusion criteria and primary outcome measure
Participants were screened on inclusion and exclusion criteria via the telephone
version of the Structured Clinical Interview for DSM-IV (SCID-I, APA, 1994; First
et al., 1996). Kappa for interrater agreement between the interviewers (psycholo-
gist/research assistants), based on audiotaped interviews, for inclusion or exclusion
was 0.77, which is indicative of good/excellent agreement. Time to recurrence was
also assessed with the SCID-I (First et al., 1996). At baseline and at ﬁve follow-up
assessments (3, 12, 24, 36 and 66 months), current and past depressive episodes
(covering the prior months) were checked from the start of the study. All interviews
were audiotaped. Two independent experienced psychiatrists who were blind to
treatment condition evaluated all participants meeting the DSM-IV criteria for
major depression. In cases of disagreement, the ratings of the psychiatrists were
used for further analyses. The kappa for interrater agreement between the
interviewers and psychiatrist on categorization of a recurrence versus no recurrence
was 0.96, indicating high agreement.2.2.2. Prediction variables2.2.2.1. Cortisol. Salivary cortisol. Subjects were asked at baseline to provide saliva
in neutral cotton salivettes (Sarstedt AG and Co, Nu¨mbrecht, Germany) at home at
three time points on two consecutive days (08:00 and 22:00, day 1, 08:00 day 2).
Saliva reliably reﬂects the blood cortisol concentrations, in a relatively stress-free
and minimally intrusive way (Kirschbaum and Hellhammer, 1994). They were
instructed to rinse their mouth with water, not to brush their teeth and remain in
the fasting state before collecting the sample, and to keep the samples in the
refrigerator until sending the samples back to the clinic. Storage took place at
–20 1C on day 3. Smoking, age, the use of antidepressants, benzodiazepines, oral
contraceptives, and bodymass index were recorded. Salivary cortisol was deter-
mined by radioimmunoassay (RIA) designed for saliva samples (IBL Hamburg). The
intra-assay variation for cortisol was intra- and inter-assay variations were 5.1%
and 6.5%, respectively of a subsample (55 of 84 patients) hormone measures that
was collected. No signiﬁcant differences on any of the patient characteristics and
time to recurrence were detected between this sample and the complete sample
(N¼84; all p’s 40.10). The following hormone continued variables were calcu-
lated: (1) mean morning cortisol and (2) evening cortisol. Since the distributions
of these measures were skewed transformed variables (by taking the natural
logarithm) were used in the survival analyses.2.2.2.2. Severity of depressive residual symptoms. The 17-item Hamilton Rating
Scale for Depression (HRSD, Hamilton, 1960) was used to assess participants’
baseline levels of depressive symptomatology (of o10). The HRSD, administered
by psychologist/research assistants who were blind to treatment condition, is a
widely used semi-structured clinical interview that covers a range of affective,
behavioral and biological symptoms and has acceptable psychometric properties
(Rabkin and Klein, 1987). Scores can range from 0 to 52. Our four interviewers
second rated 17 interviews. The Intraclass Correlation (ICC) was 0.94, indicating
high agreement. Since the distributions of these measures were skewed trans-
formed variables (by taking the natural logarithm) were used in the survival
analyses.2.2.2.3. Stress: daily hassles en childhood trauma. To measure baseline daily hassles,
the 114-item Everyday Problem Checklist was used (EPCL). The items of the EPCL
refer to stressors of daily living, particularly those in the domains of work,
parenthood, relationship, and household activities (continuous score). The EPCL
Table 1
Demographic and clinical characteristics.
Characteristic (N¼55)
Sex, female (%) 72.7
White (%) 98.0
Age (yr, mean7S.D.) 43.879.5
Years of education (mean7S.D.) 14.2 7 2.5
Single (%) 40.0
Type of current treatment (%)
Family doctor 25.5
Psychiatric help 40.0
No treatment 34.5
Antidepressant medication (%)a 58.2
SSRI (%) 58.8
SNRI (%) 17.7
TCA (%) 5.9
Other (%) 11.8
HRSD-17 score (mean7S.D.) 3.5729
Median previous episodes7 IQRb 3 (2–6)
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psychometric properties (Vingerhoets and van Tilburg, 1994).
We assessed childhood trauma covered 0–15 years (such as sexual abuse) with
the 15-item Negative Life Events Questionnaire (dichotomized score) (Kraaij and
De Wilde, 2001). This questionnaire proved to have a good predictive validity, as
the number of negative life events predicted MDD-symptom severity (Kraaij et al.,
2003).
2.3. Statistical analysis
The effect of cortisol on time to recurrence of a new episode was assessed with
Cox regression; this takes into account differences in time at risk and censoring
(no recurrence during the study period).
All analysis included the level of baseline residual symptoms (HDRS) to adjust
for state effects. To examine whether the effect of HPA-measures on time to
recurrence was modiﬁed by the level of residual symptoms, we ﬁrst tested the
interaction of cortisol (A) with residual symptoms (P); Y¼b1Aþb2Pþb3AP
assesses whether residual symptoms modiﬁes the effect of a cortisol on time to
recurrence. This is the case when the coefﬁcient of the 2-way interaction ‘cortisol
by residual symptoms term’ is statistically signiﬁcant. If this interaction term is
not signiﬁcant, Y¼b1A applies (which states that recurrence is related to cortisol).
To examine whether the effect of cortisol on time to recurrence was modiﬁed
or confounded by current stress (daily hassles) and childhood trauma, a three-step
procedure was used:Age of ﬁrst onset (yr, mean7S.D.) 27.8713.0
Co-morbid anxiety disorder (%) 10.9
Posttraumatic stress disorder (%) 0Step I: Assesses whether either stress or childhood trauma (P) modiﬁes the
effect of cortisol (A) on recurrence (model Y¼b1Aþb2Pþb3AP, this is the case
when the coefﬁcient of the 2-way interaction cortisol by stress or childhood
trauma is statistically signiﬁcant).Reported a childhood traumatic events (%)c 30.2
Reported general life events before 16 (%) 81.8
Daily hassles (geometric mean7SE)d 3.267 .09
Oral contraceptives (%) 29.1Step II: If the 2-way interaction cortisol by stress or childhood trauma
interaction term in this model is not signiﬁcant, potential effect modiﬁcation
by either stress or childhood trauma is examined (confounding effect).
Following the frequently used rule of thumb the conﬁdence intervals of the
models will be compared and are considered to be different in case they differ
more than 10 percent. Effect modiﬁcation will be reported.Benzodiazepines (%) 1.8
Menopausal hormone treatment (%) 0
BMI (geometric mean7SE)d 3.207 .02
Smoking (%) 38.2
08:00 cortisol (nmol/l, mean7S.D.)e 20.0679.61
22:00 cortisol (nmol/l, mean7S.D.) 3.1473.46
a n¼2 missings on type of antidepressant medication.
bStep III: If there is no effect modiﬁcation, Y¼b1A applies (which states that
recurrence is related to cortisol).
To examine whether potential confounders (smoking, age, the use of anti-
depressants, benzodiazepines, oral contraceptives, and body mass index) con-
founded the association of cortisol with time to recurrence, we ﬁrst examined
whether the potential confounder itself predicted recurrence (alpha level of 0.10).
Only in case of the variable predicted recurrence we examined further whether
the effect of cortisol on time to recurrence was modiﬁed or confounded by the
variable using the same procedure as described above. We used an alpha level of
0.05 for all survival analyses and 0.10 for interaction terms.
Inter quartile range.
c n¼3 missing for childhood trauma.
d Log transformed.
e Calculated mean from 2 consecutive 08:00 samples over 2 days (nmol/l,
mean7S.D.).3. Results
Table 1 presents the characteristics of this patient group. As in
most depression studies almost three quarter of the patients are
women, 40.0% are single. The mean HRSD score is 4 with a median
of 3 previous episodes. Childhood trauma was reported by 30.2%
of the sample. Not all remitted patients receive treatment (34.5%),
whereas 58.2% use antidepressant medication (58.8% of them use
SSRI’s). Benzodiazepine was used by 1 patient and no menopausal
hormone treatment was reported. In this sample 29.1% used oral
contraceptives.
There were no ‘non-detectables’ on cortisol. The detection limit
was 0.40 nmol/l. Mean morning cortisol over 2 day was 20.06 nmol/l
(S.D.¼9.61). Mean evening cortisol over 1 day was 3.14 nmol/l
(S.D.¼3.46). For the analyses log transformed data were used
because of skewed data. Morning cortisol (ln) on day one was highly
correlated to morning cortisol (ln) on day two (Pearson correlation
0.609, po0.001). There was no difference between men and women
on baseline mean cortisol levels (ln): t(53)¼0.008, p¼0.99 (Men:
M¼2.88, S.D.¼ .62, Women: M¼2.88, S.D.¼ .46). Baseline mean
morning cortisol (ln) levels differed between baseline antidepressant
users versus non-users, indicating lower baseline levels of mean
morning cortisol in patients that use antidepressants: t(53)¼52.334,
p ¼ .029 (AD users: M¼2.77, S.D.¼ .57, Non-users: M¼3.04,
S.D.¼ .36). There was no signiﬁcant difference between baselineevening cortisol (ln) levels and antidepressant users versus non-
users, though there was a difference on the level of a trend,
indicating lower baseline levels of evening cortisol in patients that
use antidepressants: t(53)¼1.973, p¼ .054 (AD users: M¼ .65,
S.D.¼ .71, Non-users: M¼1.05, S.D.¼ .77).
Relapse/recurrence
Over the 5.5 years follow-up period, 43 (78%) of our 55
participants were diagnosed with a new depressive episode. The
mean time to recurrence was 668 day (Standard Error¼95.96)
with a median of 390 day (range: 242.39-537.61).
Comparison patients with and without a prospective recurrence
A comparison between relapsed patients versus non-relapsed
patients over the 5.5 year period revealed no differences between
the two groups (for evening cortisol: (t(53) 0.564, p¼0.575;
for patients with a recurrence, evening cortisol (ln) M¼ .8473,
S.D.¼0.7908; for patients without a recurrence, M¼0.7073, S.D.¼
0.6362); for HRSD score: (t(53)1.407, p¼0.167; for patients
with a recurrence, mean HRSD score (ln) M¼2.50, S.D.¼2.97; for
patients without a recurrence, M¼3.79, S.D.¼2.78, except for
baseline mean morning cortisol levels (ln) at the level of a trend,
indicating lower baseline levels of mean morning cortisol in
patients that relapsed (t(53) 1.940, p¼0.058; for patients with a
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for patients without a recurrence, M¼3.126, S.D.¼0.5058).
3.1. Prediction of time to recurrence by cortisol
Mean morning cortisol predicted time to recurrence after
correction for residual depressive symptoms (after correction for
residual depressive symptoms: Wald(1, N¼55)¼5.889, p¼0.015,
Hazard ratio¼0.442, 95% CI¼0.228–0.855, without including
residual symptoms: Wald(1, N¼55) ¼3.374, p¼0.066, Hazard
ratio¼0.554, 95% CI¼0.295–1.040). Lower mean morning cortisol
levels predicted earlier recurrence. Evening cortisol did not predict
time to recurrence (after correction for residual depressive symp-
toms: Wald(1, N¼55)¼0.094, p¼0.759, Hazard ratio¼0.938, 95%
CI¼0.623–1.412, without including residual symptoms: Wald(1,
N¼55)¼0.052, p¼0.820, Hazard ratio¼0.956, 95% CI¼0.648–
1.409). Both interaction terms (i.e. mean morning cortisol by
residual symptoms and evening cortisol residual symptoms) did
not predict time to recurrence (both p’s41).
As presented in Table 2 none of the potential confounders
(i.e. anti-depressant use, use of oral contraceptives smoking, BMI
and age) was associated to time to recurrence. So we detected no
moderation or confounding effect on the association between
mean morning cortisol and recurrence.
3.2. Association with daily hassles and childhood life events and
traumatic childhood events
Mean morning cortisol is correlated at the level of a trend with
having traumatic experienced life events before the sixteenthTable 2
Potential confounders of the association between mean morning cortisol and recurren
Predictora
Univariate prediction
of relapse
Mean morning
cortisol
Anti-depressant use
Wald 5.889 0.018
b 0.817 0.042
Exp(b) 0.442 0.59
P 0.015 0.892
CI 0.228–0.855 0.522–1.762
n All models corrected for residual symptoms.
a Continuous variables: mean morning cortisol, residual symptoms, age, BMI (all lo
Table 3
Role of stress and childhood trauma on the association between mean morning cortiso
Variablea Model 1b
Potential confounder by m
morning cortisol interactio
Daily hassles Wald 2.276
b 0.874
Exp(b) 0.417
P 0.131
CI 0.134–1.299
Childhood traumatic events* Wald 0.177
b 0.153
Exp(b) 1.165
P 0.674
CI 0.571–2.376
a Continuous variables: mean morning cortisol, residual symptoms, daily hassles (
b Model I: ln mean morning cortisol by potential confounder interaction, corrected
corrected for residual symptoms. Model III: ln mean morning cortisol corrected for res
n n¼3 missing.
nn Confounding effect for traumatic childhood events trauma.year (mean morning cortisol (ln) dichotomized using a median
split; Kappa 0.231 p¼0.071). In the group with lower
cortisol, 42.3% (11/26) experienced traumatic life events before
age 16, while for the group with higher cortisol this was 19.2%
(5/26).
As shown in Table 3 the number of daily hassles did not modify
the association between recurrence and mean morning cortisol
corrected for residual symptoms (interaction term:Wald(1, N¼55)¼
2.276, p¼0.131, Hazard ratio¼ .417, 95% CI¼0.134–1.299). In addi-
tion, daily hassles did not confound the association between lower
mean morning cortisol and earlier recurrence (adjusted hazard
for cortisol; Wald(1, N¼55)¼6.546, p ¼0.011, Hazard ratio¼0.418,
95% CI¼0.214–0.815).
As shown in Table 3 (n¼3 missing), having experienced traumatic
events in childhood (for example sexual abuse) did not modify
the association between recurrence and mean morning cortisol
corrected for residual symptoms (interaction term:Wald(1, N¼52)¼
1.77, p¼0.674, Hazard ratio¼1.165, 95% CI¼0.571–2.376). It did
however confound this association (410% change of conﬁdence
intervals of cortisol including childhood trauma in the model):
including childhood trauma Wald(1, N¼52)¼3.641, p¼ .056, Hazard
ratio¼0.512, 95% CI¼0.258–1.018 versus 95% CI without childhood
trauma: Wald(1, N¼52)¼5.789, p¼0.016, Hazard ratio¼0.439,
95% CI¼0.224–0.858. An exploratory multivariate analysis including
mean morning cortisol, daily hassles and childhood trauma (after
correction for residual symptoms) revealed that all variables inde-
pendently (interaction terms could not be tested) predict time to
recurrence (n¼52, n¼3 is missing: for total model p¼0.001, for
mean morning cortisol p¼0.051, for childhood trauma, p¼0.024 and
for daily hassles p¼0.055).ce* (N¼55).
Contraceptive
use
Smoking Body Mass
Index (BMI)
Age
1.723 0.034 1.138 0.079
0.428 0.059 0.906 0.005
0.652 1.061 0.404 0.995
0.189 0.853 0.286 0.779
0.344–1.235 0.568–
1.979
0.077–
2.135
0.961–
1.030
g transformed because of skewness), all the other variables were dichotomous.
l and recurrence (N¼55).
Model 2 Model 3
ean
n
Potential
confounder
Mean morning
cortisol
Mean morning
cortisol
3.748 6.546 5.889
0.466 0.872 0.817
1.594 0.418 0.442
0.053 0.011 0.015
0.994–2.555 0.214–0.815 0.228–0.855
4.939 3.641 5.789
0.392 0.669 0.824
1.480 0.512 0.439
0.026 0.056 0.016
1.047–2.091 0.258–1.018** 0.224–0.858
all log transformed because of skewness), dichotomous: Childhood trauma.
for residual symptoms. Model II: ln mean morning cortisol, potential confounder
idual symptoms.
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We examined the predictive value of HPA-axis over 5.5 years in
patients with remitted recurrent depression. In line with our
expectation we found that relatively lower mean morning cortisol
levels predicted within this patient group, earlier time to recurrence
over this 5.5-year period, while evening cortisol did not predict
time recurrence. A multivariate analyses revealed that mean
morning cortisol, childhood trauma and daily hassles tend to be
independently associated to recurrence. However, interaction
terms in this multivariate model could not be tested given the
relatively small sample (n¼55). Though childhood trauma slightly
confounded the prediction of recurrence by mean morning cortisol.
This supports prior ﬁndings that chronicity and recurrence in
depression is associated with lower levels of cortisol (Oldehinkel
et al., 2001; Ahrens et al., 2008; Vreeburg, 2010). Ahrens et al.
(2008) reported hypoactivity over a remitted recurrently depressed
cohort with exclusively women. We found no signiﬁcant differ-
ences in mean morning cortisol levels between men and women.
The impact of stress in recurrent depression could explain why
a relatively low HPA-Axis activity is a risk factor for recurrence in
recurrent depression. In recurrent depression daily hassles and
life events seem to predict subsequent recurrence (Ormel et al.,
2001; Bockting et al., 2006a,b). Daily hassles and life events may
result in states of chronic stress exposure which may cause an
allostatic load, i.e., ﬂuctuation and heightened neural or endocrine
response, as pointed out by Fava (1999).
Having experienced traumatic events in childhood might have a
crucial role in the HPA-axis, in dealing with stress and subsequently
in onset and course of depression (chronicity). Childhood traumas
have been reported before as an independent determinant of
chronicity of depression (Wiersma et al., 2009). This is in line with
our ﬁnding that lower cortisol levels within this patient group were
associated to having experienced more traumatic life events
in childhood and predicted prospective recurrence (42.3% of the
patients with lower cortisol experienced traumatic life events
while 19.2% experienced childhood trauma in patients with higher
cortisol). Treadway et al. (2009) suggest that chronic stress sub-
sequent to childhood maltreatment may serve to initiate glucocor-
ticoid-related injury to the anterior cingulate cortex. This damage
may impair cortico-limbic circuits involved in emotion regulation.
Carpenter and colleagues reported that especially emotional
childhood abuse might dampen cortisol reactivity that is cumu-
lative overtime (Carpenter et al., 2009), which has been shown in
a study amongst 230 adults without major Axis I Disorders that
completed the Dex/CRH test. Unfortunately, we do not have data
on emotional abuse in childhood to examine this hypothesis.
However, we did indeed ﬁnd an indication that childhood trauma
in general (such as sexual abuse) slightly confounded the predic-
tion of recurrence by mean morning cortisol.
Miller et al. (2007) showed in their meta-analysis on the
impact of chronic stress on HPA function that much of the
variability in HPA response is attributable to stressor features.
Timing is a critical element, as hormonal activity is elevated at
stress onset but reduced as time passes. Stress that threatens
physical integrity is traumatic in nature, and is largely uncontrol-
lable that elicits a high, ﬂat diurnal proﬁle of cortisol secretion.
Together, this can result in poor regulation of stress, and could
play a role in both the initiation of depression and increased
vulnerability to recurrence. Alternatively, lowered cortisol levels
in the remitted state may reﬂect a direct biological vulnerability
for recurrent depressive episodes which, consequently, heightens
the impact of daily hassles in these patients. To explain our
ﬁndings, one might hypothesize that during the course of recur-
rent depression, an initial HPA overdrive may lead to increased
basal cortisol levels associated with an abrupt stress response,and after remission of depression, may be followed by a dam-
pened/muted basal as well as stress-induced HPA activity.
Alternatively, our ﬁndings if replicated might indicate the hypo-
thetical existence of different depression phenotypes (Bouhuys et al.,
2006). One type may be characterized by normalization of HPA
system function or even by evolving HPA hypo-activity associated
with stable remission. Another type may show sustained HPA
system dysfunction after remission as well as an increased risk for
recurrence. One might speculate that our group of remitted patients
included more subjects from the second group, giving insight in
stress system regulation in this subtype.
Besides antidepressant medication, psychological interventions
in the maintenance phase, such as brief cognitive therapy either
added to regular care or medication, and Mindfulness-Based Cogni-
tive therapy, are helpful in preventing relapse/recurrence (Bockting
et al., 2005, 2009; Vittengl et al., 2007; Guidi et al., 2011). As previ-
ously reported (Bockting et al., 2006a,b) in patients who received
additional preventive cognitive therapy, cortisol levels did not
predict time to relapse. Possibly in patients who were treated with
psychological preventive interventions, the impact of daily hassles
on recurrence is reduced, and therefore the extent to which patterns
of depressive thinking were reactivated is limited, resulting in the
absence of lowered cortisol as a risk factor for recurrence.
This study contains strengths and weaknesses. Strengths of the
study are the fact that our cohort included exclusively patients with
at least two previous episodes and was followed prospectively for
5.5 years. Further, we included patients with recurrent depression
remitted on variety of treatments or no treatment at all, without
restrictions on medication status at entry to the study. As such, this
study was designed to maximize external validity, which suggests
good generalizability of the ﬁndings. However, there are also several
limitations to address. First, the relatively small sample size redu-
cing the power to detect weaker associations between recurrence
and the interaction between cortisol, daily stress and experienced
childhood trauma. However, longitudinal studies in this high risk
group for recurrence (i.e. patients with recurrent depression) are
scarce. Second, we have no data on waking time and sleep quality of
the subjects. Third, we only measured one morning concentration
(mean of 2 day morning assessments) instead of the whole cortisol
awakening response, and so based our cortisol course over the day
estimation on two measurements. However, all our effects were
estimated on values measured using identical methodology. Fourth,
our results restrict to prediction of recurrence within this sample and
does not include a comparison to a normal control group.
Fifth, this sample included a mixed group of patients that used
antidepressants and patients that did not use this. In line with
other studies (Holsboer and Barden, 1996; Michelson et al., 1997;
Deuschle et al., 2003; Vreeburg et al., 2009; Manthey et al., 2011), we
found an association between use of antidepressants and decreased
cortisol levels. However, in line with Vreeburg et al.’s (2009) ﬁndings
were comparable after controlling for the confounding effect of use
of antidepressants. Finally, we assessed childhood trauma by using a
self-report questionnaire rather than an interview. This might under-
score the actual prevalence of childhood trauma.
In sum, our study adds further support for the predictive role of
HPA axis dysregulation, i.e. lower morning cortisol levels, in relapse
and recurrence of recurrent depression. This effect could not be
explained by state dependent depressive residual symptoms,
though residual symptoms slightly confounded the association.
Childhood traumatic life events might have an impact on the
HPA-axis and thereby on the impact of stress as risk factor for
recurrence in depression. Replication is necessary to conﬁrm the
impact of childhood traumatic life events on the HPA-axis and
thereby on prospective recurrence. Future studies are needed to
examine this speciﬁc pathogenic role of cortisol in interaction
with stress and childhood trauma as risk factor for recurrence
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